The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

October 1, 2020 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ajt/shutterstock.com

ajt/shutterstock.com

Introduction & Objectives
The primary treatment goals for rheumatoid arthritis (RA)—symptom reduction and prevention of joint damage leading to permanent disability—require intervention with disease-modifying anti-rheumatic drugs (DMARDs), including first-line conventional synthetic DMARDs, biologic DMARDs and targeted synthetic DMARDs.

You Might Also Like
  • Upadacitinib Promising for RA Patients
  • FDA Approves Upadacitinib for RA
  • Upadacitinib + Methotrexate & Other csDMARDs in RA Patients
Explore This Issue
December 2020

Currently, methotrexate (MTX) is the most widely accepted initial therapy for RA, supported by its well-known long-term efficacy and safety profile, current guidelines from EULAR and the ACR, and few restrictions (i.e., cost) to patient access. However, remission is achieved in only a minority of patients receiving MTX, and acceptable disease control is achieved in at most 60% of patients. For patients who have an insufficient initial response or are intolerant of or lose response to MTX over time (~80%), conventional synthetic DMARDs other than MTX or the addition of a biologic DMARD or targeted synthetic DMARD to a conventional synthetic DMARD is recommended to rapidly attenuate the potentially irreversible impact of active disease. Previous studies in MTX-naive patients with moderately to highly active RA and poor prognosis (i.e., seropositivity for rheumatoid factor [RF] and anti-citrullinated protein antibodies [ACPAs] and radiographic damage at baseline) have shown that MTX monotherapy was less effective than its combination treatments.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The JAK enzymes (JAK1, JAK2, JAK3 and TYK2) are important mediators of multiple cytokine-signaling pathways for normal cellular processes, as well as for immune-mediated inflammation. Orally administered JAK inhibitors (targeted synthetic DMARDs; jakinibs) are approved for their established efficacy as monotherapy and combination therapy (with conventional synthetic DMARDs), vs. biologic DMARDs, across diverse RA patient populations.

The SELECT-EARLY MTX-controlled trial was designed to study the safety and efficacy of upadacitinib, a potent, reversible jakinib, for monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to MTX.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methods
Patients (n=947) were randomized 1:1:1 to receive once-daily upadacitinib 15 mg or 30 mg or weekly MTX (7.5–20 mg/week) for 24 weeks. The primary end points were the proportion of patients who met the ACR 50% improvement criteria (ACR50) at week 12, and the proportion in whom a Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) of <2.6 was achieved at week 24. Data from the study are presented through week 24.

Results
At baseline, the median disease duration was 0.5 years (range 0–44 years). A total of 840 patients (89%) completed 24 weeks of treatment. The study met both primary end points for upadacitinib 15 mg and 30 mg vs. MTX (i.e., the ACR50 was achieved at week 12 in 52% and 56% of participants, respectively, vs. 28% [P<0.001], and DAS28-CRP <2.6 was achieved at week 24 in 48% and 50%, of participants respectively, vs. 19% [P<0.001]). Statistically significant and clinically meaningful improvements in multiple patient-reported outcomes (PROs) were recorded for both upadacitinib arms vs. MTX. Overall, 88%of subjects receiving upadacitinib 15 mg and 89% of subjects receiving 30 mg had no radiographic progression (modified total Sharp score ≤0) compared with 78% of those receiving MTX (P<0.01).

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Arthritis & Rheumatology, jakinib, Methotrexate, monotherapy, Rheumatoid Arthritis (RA), upadacitinib, upadacitinib monotherapyIssue: December 2020

You Might Also Like:
  • Upadacitinib Promising for RA Patients
  • FDA Approves Upadacitinib for RA
  • Upadacitinib + Methotrexate & Other csDMARDs in RA Patients
  • Upadacitinib Monotherapy Effective in Refractory Rheumatoid Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)